金属硫蛋白1负向调控葡萄糖刺激的胰岛素分泌,在β细胞代偿与衰竭中差异表达
该研究探讨金属硫蛋白(MT)基因在β细胞代偿与衰竭中的作用。小鼠及人类胰岛数据显示,代偿状态下Mt1/Mt2表达下调,糖尿病状态下上调;Mt1-Mt2双敲除小鼠糖耐量改善、胰岛素分泌增加,而Mt1过表达小鼠GSIS受损,提示Mt1负向调控胰岛素分泌。
要点
- 肥胖代偿期胰岛Mt1/Mt2表达下调,糖尿病期上调。
- Mt1-Mt2双敲除小鼠糖耐量改善且胰岛素分泌增加。
- Mt1过表达损害葡萄糖刺激的胰岛素分泌。
核心结论
- Mt1是胰岛素分泌的负向调控因子,其下调与β细胞代偿相关,上调与β细胞衰竭和2型糖尿病相关。
研究设计与样本
- 研究比较了对照瘦小鼠与高脂饮食6周诱导肥胖小鼠、6周龄(糖尿病前期)和16周龄(糖尿病发病后)db/db小鼠与db/+对照、16周龄ob/ob肥胖非糖尿病小鼠与ob/+对照的胰岛Mt1和Mt2表达。
- 评估了2型糖尿病与非糖尿病供体人胰岛中MT1E、MT1X和MT2A表达。
- 研究了Mt1-Mt2双敲除小鼠、自然启动子过表达Mt1的转基因小鼠(Tg-Mt1)及相应对照小鼠,并在MIN6细胞中用siRNA抑制MT1和MT2。
主要发现
- 小鼠β细胞代偿模型中胰岛Mt1和Mt2 mRNA水平降低,而糖尿病db/db小鼠中升高。
- 人2型糖尿病供体胰岛MT1X mRNA水平较非糖尿病供体显著上调,MT1E和MT2A mRNA水平不变。
- 离体胰岛培养中,10-30 mmol/l葡萄糖较2-5 mmol/l下调Mt1和Mt2 mRNA及MT1和MT2蛋白水平,伴胰岛素分泌增加。
- 人胰岛中MT1E、MT1X和MT2A mRNA水平被生理及超生理浓度葡萄糖下调。
- Mt1-Mt2双敲除小鼠较野生型糖耐量改善,伴胰岛素水平升高和离体胰岛胰岛素释放增强;Tg-Mt1小鼠离体胰岛GSIS受损。
临床怎么用
- 监测胰岛Mt1表达可能有助于区分β细胞代偿与衰竭状态。
- 靶向抑制Mt1可能成为改善β细胞功能、促进胰岛素分泌的潜在策略。
局限性
- 研究主要基于小鼠模型和离体胰岛及MIN6细胞,人体数据有限。
- 未明确Mt1调控胰岛素分泌的具体分子机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The mechanisms responsible for beta cell compensation in obesity and for beta cell failure in type 2 diabetes are poorly defined. The mRNA levels of several metallothionein (MT) genes are upregulated in islets from individuals with type 2 diabetes, but their role in beta cells is not clear. Here we examined: (1) the temporal changes of islet Mt1 and Mt2 gene expression in mouse models of beta cell compensation and failure; and (2) the role of Mt1 and Mt2 in beta cell function and glucose homeostasis in mice. METHODS: Mt1 and Mt2 expression was assessed in islets from: (1) control lean (chow diet-fed) and diet-induced obese (high-fat diet-fed for 6 weeks) mice; (2) mouse models of diabetes (db/db mice) at 6 weeks old (prediabetes) and 16 weeks old (after diabetes onset) and age-matched db/+ (control) mice; and (3) obese non-diabetic ob/ob mice (16-week-old) and age-matched ob/+ (control) mice. MT1E, MT1X and MT2A expression was assessed in islets from humans with and without type 2 diabetes. Mt1-Mt2 double-knockout (KO) mice, transgenic mice overexpressing Mt1 under the control of its natural promoter (Tg-Mt1) and corresponding control mice were also studied. In MIN6 cells, MT1 and MT2 were inhibited by small interfering RNAs. mRNA levels were assessed by real-time RT-PCR, plasma insulin and islet MT levels by ELISA, glucose tolerance by i.p. glucose tolerance tests and overnight fasting-1 h refeeding tests, insulin tolerance by i.p. insulin tolerance tests, insulin secretion by RIA, cytosolic free Ca2+ concentration with Fura-2 leakage resistant (Fura-2 LR), cytosolic free Zn2+ concentration with Fluozin-3, and NAD(P)H by autofluorescence. RESULTS: Mt1 and Mt2 mRNA levels were reduced in islets of murine models of beta cell compensation, whereas they were increased in diabetic db/db mice. In humans, MT1X mRNA levels were significantly upregulated in islets from individuals with type 2 diabetes in comparison with non-diabetic donors, while MT1E and MT2A mRNA levels were unchanged. Ex vivo, islet Mt1 and Mt2 mRNA and MT1 and MT2 protein levels were downregulated after culture with glucose at 10-30 mmol/l vs 2-5 mmol/l, in association with increased insulin secretion. In human islets, mRNA levels of MT1E, MT1X and MT2A were downregulated by stimulation with physiological and supraphysiological levels of glucose. In comparison with wild-type (WT) mice, Mt1-Mt2 double-KO mice displayed improved glucose tolerance in association with increased insulin levels and enhanced insulin release from isolated islets. In contrast, isolated islets from Tg-Mt1 mice displayed impaired glucose-stimulated insulin secretion (GSIS). In both Mt1-Mt2 double-KO and Tg-Mt1 models, the changes in GSIS occurred despite similar islet insulin content, rises in cytosolic free Ca2+ concentration and NAD(P)H levels, or intracellular Zn2+ concentration vs WT mice. In MIN6 cells, knockdown of MT1 but not MT2 potentiated GSIS, suggesting that Mt1 rather than Mt2 affects beta cell function. CONCLUSIONS/INTERPRETATION: These findings implicate Mt1 as a negative regulator of insulin secretion. The downregulation of Mt1 is associated with beta cell compensation in obesity, whereas increased Mt1 accompanies beta cell failure and type 2 diabetes.
引用
- Bensellam M, Shi YC, Chan JY, et al. Metallothionein 1 negatively regulates glucose-stimulated insulin secretion and is differentially expressed in conditions of beta cell compensation and failure in mice and humans. Diabetologia. 2019. PMID: 31624901. doi:10.1007/s00125-019-05008-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。